Literature DB >> 21531001

PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.

Bożena Konopka1, Aneta Janiec-Jankowska, Ewa Kwiatkowska, Urszula Najmoła, Mariusz Bidziński, Włodzimierz Olszewski, Cyprian Goluda.   

Abstract

Alterations of the PIK3CA gene occur in endometrial carcinomas, but their role in the carcinogenesis of those malignancies is still poorly understood. In this study, PIK3CA mutations and amplification in 196 endometrioid endometrial carcinomas and 20 endometrial hyperplasias were assessed by single-strand conformation polymorphism (PCR-SSCP), sequencing, and quantitative polymerase chain reaction. Results were correlated with mutations in the PTEN, KRAS, and CTNNB1 genes and with the clinicopathologic parameters of the tumors. PIK3CA mutations were found in 39 (20%) carcinomas. Six new mutations were identified. No PIK3CA mutations were found in endometrial hyperplasias. PIK3CA amplification was observed in 24 (12.2%) carcinomas and in 2 (10%) hyperplasias. The PIK3CA mutations and amplifications (with the exception of 6 cases) occurred independently. PIK3CA mutations were significantly associated with PTEN mutations (P = .0414) and tended to be associated with CTNNB1 (P = .0833), but not with KRAS mutations. Conversely, the PIK3CA amplifications significantly negatively correlated with PTEN mutations (P = .0038) and did not coexist with CTNNB1 and KRAS mutations. The PIK3CA mutations were significantly associated with poorly differentiated tumors (P = .0423). Interestingly, PIK3CA amplifications, but not mutations, were strongly associated with older age (≥63 years, P = .0018). Our data show that mutations and amplification of PIK3CA are significant genetic alterations in endometrioid endometrial carcinomas associated with adverse clinicopathologic parameters (grade and stage). These data also demonstrate that PIK3CA mutations cooperate with PTEN mutations, suggesting an additive effect to PTEN, whereas PIK3CA amplification can, as an isolated event, enable the development of those tumors. Moreover, for the first time, a possible role of PIK3CA amplification in initiation and progression of endometrial carcinomas in older women is suggested, but this preliminary suggestion requires further research.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531001     DOI: 10.1016/j.humpath.2010.01.030

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

Review 1.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

2.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

3.  Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Authors:  Kimberly K Leslie; Michael W Sill; Heather A Lankes; Edgar G Fischer; Andrew K Godwin; Heidi Gray; Russell J Schilder; Joan L Walker; Krishnansu Tewari; Parviz Hanjani; Ovadia Abulafia; Peter G Rose
Journal:  Gynecol Oncol       Date:  2012-08-07       Impact factor: 5.482

4.  [p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans].

Authors:  P J Wild
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.

Authors:  Peter J Wild; Kristian Ikenberg; Thomas J Fuchs; Markus Rechsteiner; Strahil Georgiev; Niklaus Fankhauser; Aurelia Noske; Matthias Roessle; Rosmarie Caduff; Athanassios Dellas; Daniel Fink; Holger Moch; Wilhelm Krek; Ian J Frew
Journal:  EMBO Mol Med       Date:  2012-06-08       Impact factor: 12.137

Review 6.  Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.

Authors:  Irene Brana; Lillian L Siu
Journal:  BMC Med       Date:  2012-12-11       Impact factor: 8.775

7.  FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Authors:  Sara A Byron; Michael Gartside; Matthew A Powell; Candice L Wellens; Feng Gao; David G Mutch; Paul J Goodfellow; Pamela M Pollock
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

8.  Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Authors:  Anna Berg; Erling A Hoivik; Siv Mjøs; Frederik Holst; Henrica M J Werner; Ingvild L Tangen; Amaro Taylor-Weiner; William J Gibson; Kanthida Kusonmano; Elisabeth Wik; Jone Trovik; Mari K Halle; Anne M Øyan; Karl-Henning Kalland; Andrew D Cherniack; Rameen Beroukhim; Ingunn Stefansson; Gordon B Mills; Camilla Krakstad; Helga B Salvesen
Journal:  Oncotarget       Date:  2015-01-20

9.  Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.

Authors:  Vivian M Spaans; Marjolijn D Trietsch; Alexander A W Peters; Michelle Osse; Natalja Ter Haar; Gert J Fleuren; Ekaterina S Jordanova
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

10.  Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

Authors:  I Ray-Coquard; L Favier; B Weber; C Roemer-Becuwe; P Bougnoux; M Fabbro; A Floquet; F Joly; A Plantade; D Paraiso; E Pujade-Lauraine
Journal:  Br J Cancer       Date:  2013-04-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.